Biotech entity
ICOTYDE is most often covered alongside Johnson & Johnson, which appears in 1 of these 2 stories. The 87-day window averages about 0.2 stories each week. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window.
Last mentioned: 3d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
ICOTYDE is most often covered alongside Johnson & Johnson, which appears in 1 of these 2 stories. The 87-day window averages about 0.2 stories each week. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. At 6, the average consequence score sits below the same-window beat average of 6.1. The clearest coverage concentration is fda-approval: 1 of 2 stories, with the rest divided among 1 other category. ICOTYDE appears in 2 tracked Biotech stories published from June 14, 2026 through September 8, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 318 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ICOTYDE. Shared-story counts are live from our verified record — not editorial picks.
Protagonist's board authorized a $300 million repurchase, backed by $849.5 million in cash and royalty streams from two FDA-approved drugs. For biotech observers, the move marks a shift from cash burn to capital return as partnered products generate milestone and royalty income.
Source: finanznachrichten.de · Seeking Alpha
Protagonist Therapeutics has transitioned from binary clinical risk to execution risk, with ICOTYDE's FDA approval and rusfertide's Priority Review. Backed by $620 million in cash, the company's validated peptide platform and royalty-based revenue model offer a compelling biotech investment thesis.
ICOTYDE is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
